The Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease in Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis
Issued Date
2025-02-01
Resource Type
eISSN
20770383
Scopus ID
2-s2.0-85218859252
Journal Title
Journal of Clinical Medicine
Volume
14
Issue
4
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Clinical Medicine Vol.14 No.4 (2025)
Suggested Citation
Untaaveesup S., Kantagowit P., Ungprasert P., Kitlertbanchong N., Vajiraviroj T., Sutithavinkul T., Techataweewan G., Eiumtrakul W., Threethrong R., Chaemsupaphan T., Pratchyapruit W., Sriphrapradang C. The Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease in Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine Vol.14 No.4 (2025). doi:10.3390/jcm14041374 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/105559
Title
The Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease in Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis
Corresponding Author(s)
Other Contributor(s)
Abstract
Background/Objectives: Psoriasis is a chronic immune-mediated skin disease associated with several metabolic comorbidities. Metabolic dysfunction-associated steatotic liver disease (MASLD) is also linked to psoriasis, but evidence regarding the severity of this association remains inconclusive. This meta-analysis aimed to investigate the relationship between MASLD and varying severities of psoriasis. Methods: We conducted an extensive search of four databases, MEDLINE, EMBASE, OSF, and ClinicalTrials.gov to identify relevant published articles assessing the risk of prevalent MASLD in patients with moderate-to-severe psoriasis up to April 2024. Effect estimates from each included study were combined together to calculate a pooled effect estimate for the meta-analysis using the generic inverse variance method of DerSimonian and Laird. Results: This meta-analysis included eight studies with a total of 109,806 participants. A 4.01-fold increased risk of prevalent MASLD was observed in patients with moderate-to-severe psoriasis compared to those without psoriasis (95% CI: 2.17, 7.77; I2 = 67%, p < 0.0001). The evidence supporting this outcome had low certainty. Conclusions: An incremental trend of MASLD was observed in patients with moderate-to-severe psoriasis. Routine screening for MASLD should be emphasized in this population.